Akums Reports Q4 FY26 and Full Year FY26 Results: Healthy Growth Driven by CDMO Segment

Akums Reports Q4 FY26 and Full Year FY26 Results: Healthy Growth Driven by CDMO Segment​

New Delhi, May 2026: Akums Drugs and Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its financial results for the fourth quarter and the full year ended March 31, 2026. The company reported a steady performance, noting healthy revenue growth and improved operating profitability, particularly driven by its core domestic CDMO business.

For the fourth quarter of FY26, Akums reported an operating revenue of ₹1,158 crore. This represents a 9.7% year-on-year growth compared to ₹1,056 crore in Q4 FY25. Adjusted EBITDA stood at ₹152 crore, marking a 61.6% year-on-year increase from ₹94 crore in the same quarter last year. Furthermore, the Adjusted EBITDA margin improved to 13.1% from 8.9%. Adjusted Profit After Tax (PAT) was ₹83 crore, showing a 135% year-on-year growth over ₹35 crore in Q4 FY25, with the Adjusted PAT margin improving to 7.0% from 3.3%.

On a full-year basis, FY26 operating revenue reached ₹4,359 crore, achieving 5.9% year-on-year growth over ₹4,118 crore recorded in FY25. Adjusted EBITDA increased 13.3% year-on-year to ₹522 crore, while Adjusted PAT grew 27.3% year-on-year to ₹276 crore.

Segment Performance Highlights​

The CDMO segment was identified as the key growth driver during Q4 FY26. CDMO revenue grew to ₹952 crore, significantly up from ₹840 crore in Q4 FY25. CDMO EBITDA increased 54.9% year-on-year to ₹137 crore, while the EBITDA margin improved to 14.4% from 10.6%. This strong performance was attributed to better capacity utilisation, continued customer engagement, and focused execution.

Other key segments showed varied performance:

• Domestic Branded Formulations: This business remained stable in Q4 FY26, reporting revenue of ₹102 crore compared to ₹104 crore in Q4 FY25. For the full year, the segment saw improved profitability, with revenue growing 2.9% year-on-year to ₹446 crore and EBITDA increasing 17.0% to ₹90 crore.
• International Branded Formulation: Quarterly revenue saw moderate change, reporting ₹36 crore in Q4 FY26 against ₹40 crore in Q4 FY25. For FY26, revenue remained flat at ₹143 crore, although EBITDA increased 32.3% year-on-year to ₹36 crore.
• Trade Generics: This segment began turning a corner with positive EBITDA of Rs 1.4 crore in Q4 FY26. For the full year, the EBITDA loss narrowed sharply to Rs 10 crore from Rs 28 crore in FY25.
• Active Pharmaceutical Ingredients (API): The API business faced pricing pressure. In Q4 FY26, API revenue was ₹41 crore, down from ₹50 crore in Q4 FY25, and posted an operating loss of 12 crore. For FY26, API revenue decreased year-on-year, and the EBITDA loss slightly reduced from ₹44 crore in FY25 to ₹40 crore in FY26.

Strategic Milestones and Board Recommendation​

The company announced significant progress toward establishing itself as a global pharmaceutical entity. During FY26, Akums achieved its first commercial supply of formulations to Europe. The company strengthened its regulated market presence by securing EU GMP certifications for its Oral Solids and Oral Liquids facilities and obtaining its first UK MHRA approval for Rivaroxaban. Additionally, the Akums injectable plant received Brazil ANVISA approval, and the ground-breaking of the Zambia pharmaceutical plant marked a major international milestone.

The Board also recommended dividends for the year FY25-26: a final dividend of INR 1 per equity share (50% of the face value of INR 2) and a special dividend of INR 2 per equity share (100% of the face value of INR 2).

Commenting on the results, Mr. Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., stated, "FY26 has been a year of steady progress for Akums. We delivered healthy growth in revenue and profitability while continuing to build capabilities for the long term. Our regulatory milestones, international developments and strong domestic performance reflect our focus on building Akums as a global pharmaceutical company and a trusted partner for our clients."

Mr. Sandeep Jain, Managing Director, added, "The Q4FY26 and full year performance showed improvement across key operational parameters. Our CDMO business continued to perform well as we remain focused on better capacity utilisation, cost discipline and future growth. We are working on multiple digitalization and automation initiatives which will deliver long-term value for the organization."

For a detailed comparison of the financial metrics, the following table summarizes the operational and profitability results:

AKUMS Stock Price Movement​

Akums Drugs and Pharmaceuticals Limited shares today slipped by 1.59% to settle at ₹527.9. The stock saw considerable activity, trading on a total volume of 1.02 million shares.